COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
26/03/2024
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, [...]
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26/03/2024
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]
OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
26/03/2024
WARSAW, Ind., March 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
26/03/2024
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham- [...]
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
26/03/2024
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
26/03/2024
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood [...]
MannKind Announces CFO Transition
26/03/2024
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024 Christopher Prentiss appointed Chief Financial Officer, [...]
Stryker announces Annual Meeting of Shareholders
26/03/2024
Portage, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2024 Annual Meeting of Shareholders is scheduled as follows: Thursday, May 9, 2024 – 9:30 a.m. Eastern Time The Meeting will be held [...]
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
26/03/2024
DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
26/03/2024
WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results. On December [...]
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
26/03/2024
Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based [...]
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
26/03/2024
PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth [...]
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/03/2024
LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby [...]
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
26/03/2024
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 Demonstrated the versatility of Korro’s RNA editing platform [...]
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
26/03/2024
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non- [...]
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
26/03/2024
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in [...]
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26/03/2024
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and [...]
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
26/03/2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and [...]
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26/03/2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]

Pages